Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17544610 | 0.81 | HSP90B1 (0.47) | HSP90AA1HSP90B1 | |
| SCHEMBL17670437 | 0.80 | HSP90AA1 (0.42) | HSP90AA1HSP90B1AGTR1AGTR2RAB9A | |
| SCHEMBL17544839 | 0.75 | HSP90B1 (0.43) | HSP90AA1HSP90B1GRM2TP53 | |
| SCHEMBL17544781 | 0.67 | GRM2 (0.36) | AGTR1AGTR2SSTR4GRM2TP53 | |
| SCHEMBL3977347 | 0.65 | HSP90AA1 (0.40) | HSP90AA1HSP90B1RAB9AGRM2OPRD1 | |
| SCHEMBL17545037 | 0.65 | GRM2 (0.35) | AGTR1AGTR2GRM2 | |
| SCHEMBL17549883 | 0.62 | HSP90AA1 (0.44) | HSP90AA1HSP90B1RAB9AGRM2TP53 | |
| SCHEMBL1636495 | 0.62 | HDAC3 (0.40) | AGTR1AGTR2SSTR4 | |
| SCHEMBL7186268 | 0.61 | RAB9A (0.67) | HSP90AA1HSP90B1RAB9AOPRD1TP53 | |
| SCHEMBL30964961 | 0.60 | HDAC3 (0.39) | SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802941-B2 | Compounds and methods for inhibiting histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | PHF8, KDM3A, PHF2 | HSP90AA1 820/4885HSP90B1 2301/4885AGTR1 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.